Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 3

Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease

NCT04114981 · View on ClinicalTrials.gov ↗

Study Summary

This phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery. Single fraction stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Fractionated stereotactic radiosurgery delivers multiple, smaller doses of radiation therapy over time. This study may help doctors find out if fractionated stereotactic radiosurgery is better or worse than the usual approach with single fraction stereotactic radiosurgery.

Interventions

  • OTHER Questionnaire Administration
  • PROCEDURE Quality-of-Life Assessment
  • RADIATION Single Fraction Stereotactic Radiosurgery
  • RADIATION Fractionated Stereotactic Radiosurgery

Study Locations (20)

Arizona

  • Banner MD Anderson Cancer Center — Gilbert
  • Banner Thunderbird Medical Center — Glendale
  • Banner-University Medical Center Phoenix — Phoenix
  • Mayo Clinic Hospital in Arizona — Phoenix
  • Mayo Clinic in Arizona — Scottsdale
  • University of Arizona Cancer Center-North Campus — Tucson

California

  • UC San Diego Moores Cancer Center — La Jolla
  • Los Angeles County-USC Medical Center — Los Angeles
  • USC / Norris Comprehensive Cancer Center — Los Angeles
  • Epic Care Cyberknife Center — Walnut Creek

Arkansas

  • Mercy Hospital Fort Smith — Fort Smith
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro

Colorado

  • University of Colorado Hospital — Aurora
  • UCHealth Memorial Hospital Central — Colorado Springs

Delaware

  • Helen F Graham Cancer Center — Newark
  • Beebe Health Campus — Rehoboth Beach

Alabama

  • University of Alabama at Birmingham Cancer Center — Birmingham

Alaska

  • Anchorage Radiation Therapy Center — Anchorage

Connecticut

  • Yale University — New Haven

Trial Details

FieldValue
Enrollment Target 242 participants
Start Date 2019-11-19
Est. Completion 2028-03
Phase Phase 3

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04114981

The ClinicalTrials.gov registry entry for NCT04114981 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 147 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Metastatic Malignant Neoplasm in the Brain appearing as the primary indexed condition, and to 4 interventions — of which Questionnaire Administration is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04114981 reports 20 study locations spanning 9 distinct geographic areas — top geographies include Arizona, California, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04114981 about?

NCT04114981 is a clinical study titled "Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease". This phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery. Single fraction stereotactic radiosur...

What is the current status of trial NCT04114981?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2019-11-19. Estimated completion is 2028-03.

What conditions does trial NCT04114981 study?

This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Brain. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04114981?

The interventions under investigation include: Questionnaire Administration (OTHER), Quality-of-Life Assessment (PROCEDURE), Single Fraction Stereotactic Radiosurgery (RADIATION), Fractionated Stereotactic Radiosurgery (RADIATION). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04114981?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 147 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04114981 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial